These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19721171)

  • 1. [Prostatic specific antigen (PS), pro-inflammatory cytokines, and prostatic pathology (benign prostatic hyperplasia and cancer). Relationship with malignancy].
    Cansino Alcaide JR; Vera San Martín R; Rodríguez de Bethencourt Codes F; Bouraoui Y; Rodríguez Berriguete G; Oueslati R; Pérez-Utrilla M; De la Peña Barthel J; Paniagua Gómez-Alvarez R; Royuela García M
    Arch Esp Urol; 2009 Jun; 62(5):359-66. PubMed ID: 19721171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pro-inflammatory cytokines and prostate-specific antigen in hyperplasia and human prostate cancer.
    Bouraoui Y; Ricote M; García-Tuñón I; Rodriguez-Berriguete G; Touffehi M; Rais NB; Fraile B; Paniagua R; Oueslati R; Royuela M
    Cancer Detect Prev; 2008; 32(1):23-32. PubMed ID: 18400418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokine profiling identifies an interaction of IL-6 and IL-1α to drive PSMA-PSA prostate clones.
    Jemaa AB; Bouraoui Y; Rais NB; Nouira Y; Oueslati R
    Immunobiology; 2016 Dec; 221(12):1424-1431. PubMed ID: 27451139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokine variations in patients with hormone treated prostate cancer.
    Wise GJ; Marella VK; Talluri G; Shirazian D
    J Urol; 2000 Sep; 164(3 Pt 1):722-5. PubMed ID: 10953133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profile of NF-κBp(65/NFκBp50) among prostate specific antigen sera levels in prostatic pathologies.
    Bouraoui Y; Ben Jemaa A; Rodriguez G; Ben Rais N; Fraile B; Paniagua R; Sellemi S; Royuela M; Oueslati R
    Pathol Biol (Paris); 2012 Oct; 60(5):301-5. PubMed ID: 21889270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The profile of prostate epithelial cytokines and its impact on sera prostate specific antigen levels.
    Mechergui YB; Ben Jemaa A; Mezigh C; Fraile B; Ben Rais N; Paniagua R; Royuela M; Oueslati R
    Inflammation; 2009 Jun; 32(3):202-10. PubMed ID: 19399601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PSA-PSMA profiles and their impact on sera PSA levels and angiogenic activity in hyperplasia and human prostate cancer.
    Ben Jemaa A; Bouraoui Y; Sallami S; Banasr A; Nouira Y; Oueslati R
    Pathol Biol (Paris); 2014 Jun; 62(3):129-36. PubMed ID: 24745345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia.
    Haese A; Graefen M; Noldus J; Hammerer P; Huland E; Huland H
    J Urol; 1997 Dec; 158(6):2188-92. PubMed ID: 9366341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate.
    Royuela M; Ricote M; Parsons MS; García-Tuñón I; Paniagua R; de Miguel MP
    J Pathol; 2004 Jan; 202(1):41-9. PubMed ID: 14694520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of IAPs in prostate cancer progression: immunohistochemical study in normal and pathological (benign hyperplastic, prostatic intraepithelial neoplasia and cancer) human prostate.
    Rodríguez-Berriguete G; Fraile B; de Bethencourt FR; Prieto-Folgado A; Bartolome N; Nuñez C; Prati B; Martínez-Onsurbe P; Olmedilla G; Paniagua R; Royuela M
    BMC Cancer; 2010 Jan; 10():18. PubMed ID: 20078866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
    Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-1 (IL-1alpha and IL-1beta) and its receptors (IL-1RI, IL-1RII, and IL-1Ra) in prostate carcinoma.
    Ricote M; García-Tuñón I; Bethencourt FR; Fraile B; Paniagua R; Royuela M
    Cancer; 2004 Apr; 100(7):1388-96. PubMed ID: 15042672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies.
    Ben Jemaa A; Bouraoui Y; Sallami S; Banasr A; Ben Rais N; Ouertani L; Nouira Y; Horchani A; Oueslati R
    J Exp Clin Cancer Res; 2010 Dec; 29(1):171. PubMed ID: 21189143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
    Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
    Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha 1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia.
    Björk T; Bjartell A; Abrahamsson PA; Hulkko S; di Sant'Agnese A; Lilja H
    Urology; 1994 Apr; 43(4):427-34. PubMed ID: 7512295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PSMA-PSA clones controlled by full Akt phosphorylation (T308+,S473+) recapitulate molecular features of human prostate cancer.
    Ben Jemaa A; Bouraoui Y; Sallami S; Banasr A; Nouira Y; Horchani A; Oueslati R
    Tunis Med; 2015; 93(8-9):556-64. PubMed ID: 26815524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.
    Roehrborn CG; Boyle P; Gould AL; Waldstreicher J
    Urology; 1999 Mar; 53(3):581-9. PubMed ID: 10096388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer.
    Drachenberg DE; Elgamal AA; Rowbotham R; Peterson M; Murphy GP
    Prostate; 1999 Oct; 41(2):127-33. PubMed ID: 10477909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.